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Background: Cardiovascular disease (CVD) is a common comorbidity in patients with chronic airway obstruction,
and is associated with systemic inflammation and airway obstruction. The aim of this study was to evaluate the
predictors of CVD in two different conditions causing chronic airway obstruction, asthma and COPD.
Methods: Lung function tests, clinical and echocardiographic data were assessed in 229 consecutive patients, 100
with asthma and 129 with COPD. CVD was classified into: pressure overload (PO) and volume overload (VO).
Sub-analysis of patients with ischemic heart disease (IHD) and pulmonary hypertension (PH) was also performed.
Results: CVD was found in 185 patients (81%: 51% COPD and 30% asthmatics) and consisted of PO in 42% and of
VO in 38% patients. COPD patients, as compared to asthmatics, had older age, more severe airway obstruction,
higher prevalence of males, of smokers, and of CVD (91% vs 68%), either PO (46% vs 38%) or VO (45% vs 30%).
CVD was associated with older age and more severe airway obstruction both in asthma and COPD. In the overall
patients the predictive factors of CVD were age, COPD, and male sex; those of PO were COPD, BMI, VC, FEV1 and
MEF50 and those of VO were age, VC and MEF50. In asthma, the predictors of CVD were VC, FEV1, FEV1 /VC%, and
PaO2, those of PO were VC, FEV1 and FEV1 /VC%, while for VO there was no predictor. In COPD the predictors of
CVD were age, GOLD class and sex, those of VO age, VC and MEF50, and that of PO was BMI. Sub-analysis showed
that IHD was predicted by COPD, age, BMI and FEV1, while PH (found only in 25 COPD patients), was predicted by
VO (present in 80% of the patients) and FEV1. In subjects aged 65 years or more the prevalence of CVD, PO and VO
was similar in asthmatic and COPD patients, but COPD patients had higher prevalence of males, smokers, IHD, PH,
lower FEV1 and higher CRP.
Conclusions: The results of this study indicate that cardiovascular diseases are frequent in patients with chronic
obstructive disorders, particularly in COPD patients. The strongest predictors of CVD are age and airway obstruction.
COPD patients have higher prevalence of ischemic heart disease and pulmonary hypertension. In the elderly the
prevalence of PO and VO in asthma and COPD patients is similar.
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Asthma and chronic obstructive pulmonary disease
(COPD) are the most common airway disorders with a
high morbidity and mortality [1,2]. According to the Glo-
bal Initiative for Asthma (GINA), approximately 300 mil-
lions people suffer from asthma [1] with a prevalence
ranging from 1 to 18%. COPD prevalence is around 6%,* Correspondence: caterina.bucca@unito.it
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reproduction in any medium, provided the orbut data are highly variable, depending on survey methods
and diagnostic criteria [3].
Both asthma and COPD are characterized by inflam-
mation, which in asthma, particularly the eosinophilic
phenotype, is predominantly confined to the airway,
while in COPD the inflammation may spill-over from
the lungs to the systemic circulation and initiate sys-
temic inflammation, as a consequence of exposure to in-
door or outdoor air pollution, cigarette smoke, or diesel
exhaust fumes [4]. A recent observation indicates that
patients with neutrophilic asthma often have systemicral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reactive protein (CRP) are considered markers of sys-
temic inflammation either in COPD or in asthma [5,6].
Systemic inflammation may be pathogenically related to
many of the comorbidities seen in chronic obstructive
airway diseases, including cardiovascular disease (CVD).
Cardiovascular complications in COPD have been attrib-
uted to the systemic effects of smoking [7]. Several ob-
servations suggest that reduced pulmonary function, no
matter what cause, is associated with increases in myo-
cardial infarction and arrhythmia [8-11]. Forced expira-
tory volume in one second (FEV1) is ranked second to
smoking and above blood pressure and cholesterol as a
predictor of all-cause and cardiovascular mortality [12].
In this regard, it has been suggested that a reduction in
FEV1 combined with smoking history better predicts
cardiovascular mortality than cholesterol [13].
The aim of this study was to evaluate prevalence and
predictors of CVD in two common airway obstructive
diseases with quite different phenotypes, asthma and
COPD.Methods
Consecutive adults outpatients with asthma and COPD, di-
agnosed according to international guidelines [1,2], were
recruited from those attending the Respiratory Pathophysi-
ology clinic of the University Hospital San Giovanni, Turin,
Italy, between January 2011 and June 2012. Inclusion cri-
teria were: age over 40 years, no acute exacerbation of
COPD and asthma in the last two months, no active pul-
monary tuberculosis or other clinically relevant lung dis-
ease. Patients aged below 40 years were excluded because
in this age range the risk of COPD is low [14].Study design
Patients underwent recording of demographic data in-
cluding age, full smoking history (current, former and
never-smokers), recording of symptoms and medication
use, clinical examination, assessment of lung function
tests, arterial blood gas analysis and venous blood
sampling for serum determination of CRP. Body mass
index was calculated on the basis of height and weight
(BMI) [15]. Asthma and COPD severity were classified
according to GINA [1] and GOLD [2] criteria, respect-
ively. Among COPD patients, those with predominant
chronic bronchitis and predominant emphysema were
identified.
Coexistent cardiovascular disease was assessed on the
basis of history, clinical and echocardiographic data. CVD
included: prior myocardial infarction and cardiovascular
accidents, documented ischaemic heart disease, pulmon-
ary or systemic arterial hypertension, heart valve disease,
echocardiographic diagnosis of pulmonary hypertension.According to the criteria of the American Heart Asso-
ciation [16], heart disease was classified as follows:
– pressure overload (PO), causing diastolic
dysfunction with preserved systolic function,
including all the conditions causing concentric left
ventricle hypertrophy, such as systemic arterial
hypertension and aortic valve disease
– volume overload (VO), including all the conditions
causing left ventricle dilatation and systolic
dysfunction, such as mitral or aortic incompetence
and ischemic heart disease.
Sub-analysis was done on patients with ischemic heart
disease (IHD) and pulmonary hypertension (PH).
Lung function tests were measured using the Baires
System (Biomedin, Padua, Italy). The values of vital cap-
acity (VC), forced expiratory volume in one second
(FEV1), and their percentage ratio (FEV1/VC%), and
maximum expiratory flow at mid VC (MEF50) were
computed and expressed as percentage of the predicted
value, according to the European Respiratory Society
guidelines [17].
Arterial blood gases, that is oxygen and carbon dioxide
partial pressures (PaO2 and PaCO2 respectively) were
measured using the analyzer GEM 4000 PREMIERE (In-
strumentation Laboratory Lexington USA).
Statistical analysis
Data were analyzed using the SPSS software package,
version 20.0 (SPSS Inc., Chicago, IL, USA) for Windows.
Discrete variables are presented as counts and percent-
ages. Continuous variables are presented as means ±
SEM, as appropriate. Comparisons between asthmatics
and COPD patients, and between patients with predom-
inant chronic bronchitis and predominant emphysema
were performed by the unpaired Student's t-test. Com-
parisons among CVD, PO and VO patients with univari-
ate ANOVA. Nominal variables were compared with the
Fisher's exact test and Pearson’s χ2. A stepwise backward
selection procedure was used to evaluate factors influent
on heart disease, using a linear regression models. The
models had as dependent variables CVD, PO or VO and
as independent predictors: disease (asthma or COPD),
age, sex, BMI, smoking habits, GINA or GOLD class,
prebronchodilator lung function tests, PaO2, CRP. The
same models were used to evaluate predictors for
asthma and COPD separately and for the sub-analysis of
patients with IHD or PH.
Statistical significance was assumed at p < 0.05.
Results
The subjects enrolled were 100 asthmatic patients and
129 COPD patients. CVD was found in 185 patients
Table 1 Comparison between general characteristics of patients with asthma and with COPD
ASTHMA N. 100 COPD N. 129 P
Age, years 59 ± 1.1 69 ± 0.9 < 0.0001
BMI 25.6 ± 0.5 26.2 ± 0.45 0.010
Male, n (%) 22 (22.0) 78 (60.5) < 0.0001
Smokers
current, n (%) 10 (10) 72 (55.8) < 0.0001
past, n (%) 8 (8) 42 (32.6) < 0.0001
Atopy,n (%) 65 (73.1) 10 (7.7) < 0.0001
Cardiovascular disease, n (%) 68 (68) 117 (90.7) 0.00002
Pressure overload, n (%) 38 (38.0) 59 (45.7) NS
Volume overload, n (%) 30 (30.0) 58 (45.0) 0.021
Subgroup IHD, n (%) 8 (8.0) 50 (38.8) < 0.001
Subgroup PH, n (%) 0 (0.0) 25 (19.4) < 0.001
VC*, % predicted 88.9 ± 1.7 83.6 ± 1.8 0.033
FEV1*, % predicted 78.0 ± 2.0 64.6 ± 1.9 < 0.0001
FEV1/VC* % 65.7 ± 1.3 57.1 ± 1.3 < 0.0001
MEF50*, % predicted 41.8 ± 2.4 29.5 ± 2.1 < 0.0001
PaO2 , mmHg 74.5 ± 1.6 71.4 ± 1.0 NS
PaCO2 , mmHg 38.4 ± 0.5 39.8 ± 0.5 NS
CRP, mg/ml 3.4 ± 0.4 7.6 ± 0.7 < 0.0001
Beta adrenergic therapy, n (%) 94 (94.9) 97 (75.2) 0.0001
Corticosteroid therapy, n (%) 95 (96) 90 (69.8) < 0.0001
Anticholinergic therapy, n (%) 22 (22) 76 (58.9) <0.0001
Value recorded before bronchodilator.
Bellocchia et al. Multidisciplinary Respiratory Medicine 2013, 8:58 Page 3 of 10
http://www.mrmjournal.com/content/8/1/58(81%), and consisted of pressure overload in 97 (42%)
and of volume overload in 88 (38%). IHD was found in
58 patients (25%), 8 asthmatics and 50 COPD, and PH
in 25 (11%), all with COPD. The general characteristics
of asthmatic and COPD patients are compared in
Table 1. The COPD group was older, and had higher
prevalence of men and of both present and past
smokers, more severe airway obstruction and higher
prevalence of heart disease, including PO, VO, IHD and
PH. Moreover, COPD patients had higher CRP valuesTable 2 Comparisons among patients without cardiovascular
volume overload (VO) in the overall study population
ASTHMA + COPD no CVD N. 44 PO N. 97 VO N. 88 Un
Age, years 53.3 ± 1.3 64.3 ± 1.0 69.1 ± 1.1
Male, n (%) 18 (40.9) 43 (44.3) 39 (44.3)
BMI 24.7 ± 0.7 26.9 ± 0.6 25.5 ± 0.5
VC, % pred. 93.4 ± 2.2 85.1 ± 1.7 83.5 ± 2.4
FEV1, % pred. 82.6 ± 2.5 70.7 ± 2.1 64.8 ± 2.4
FEV1/VC % 67.6 ± 1.7 61.5 ± 1.5 56.7 ± 1.6
MEF50, % pred 49.5 ± 4.1 35.8 ± 2.3 25.8 ± 2.3
CRP, mg/ml 3.1 ± 0.6 5.9± 0.6 7.3 ± 1.0
NS not statistically significant.than asthmatics, suggestive of systemic inflammation.
No significant difference in PaO2 and PaCO2 was found
between the two groups.
The comparisons among subgroups with no cardiovas-
cular disease (No CVD), with PO and VO in the overall
patients, in asthma and in COPD are reported in the
Tables 2, 3 and 4.
In the overall patients (Table 2), both PO and VO, as
compared with no CVD, were associated with older age
and lower VC, FEV1, FEV1/VC and MEF50 and higherdisease (no CVD), with pressure overload (PO) and
ivariate ANOVA no CVD vs PO no CVD vs VO PO vs VO
< 0.0001 < 0.0001 < 0.0001 0.002
NS NS NS NS
0.038 0.028 NS NS
0.011 0.005 0.006 NS
< 0.0001 0.001 < 0.0001 NS
< 0.0001 0.015 < 0.0001 0.032
< 0.0001 0.002 < 0.0001 0.003
0.011 0.009 0.007 NS
Table 3 Comparisons among patients without cardiovascular disease (no CVD), with pressure overload (PO) and
volume overload (VO) in asthma
ASTHMA no CVD N. 32 PO N. 38 VO N. 30 Univariate ANOVA no CVD vs PO no CVD vs VO PO vs VO
Age, years 51.3 ± 1.4 60.7 ± 1.6 63.1 ± 2.1 < 0.0001 < 0.0001 < 0.0001 NS
Male, n (%) 9 (28.1) 6 (15.8) 7 (23.3) NS NS NS NS
BMI 24.5 ± 0.8 26.5 ± 0.9 25.7 ± 0.7 NS NS NS NS
VC, % pred. 94.0 ± 2.8 84.7 ± 2.2 89.0 ± 3.7 NS 0.011 NS NS
FEV1, % pred. 85.4 ± 2.9 76.7 ± 2.9 73.8 ± 4.5 0.029 0.041 0.032 NS
FEV1/VC % 68.9 ± 1.7 65.7 ± 2.0 61.2 ± 2.9 0.042 NS 0.010 NS
MEF50, % pred 51.3 ± 4.2 37.8 ± 3.5 35.8 ± 4.5 0.017 0.016 0.015 NS
CRP, mg/ml 2.5 ± 0.5 4.1 ± 0.8 3.5 ± 0.8 NS NS NS NS
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found in asthmatic patients (Table 3). In COPD patients
(Table 4) the significant associations were with age and
MEF50, %.
The results of linear regression analysis are shown in
Table 5 for the whole patients, in Table 6 for asthmatic
patients and in Table 7 for COPD patients. In the overall
patients predictive factors of CVD were: age, COPD, and
sex; those of PO were COPD, BMI, VC, FEV1 and
MEF50 and those of VO were age, class of disease sever-
ity, VC and MEF50. In asthma, the strongest predictors
of CVD were VC, FEV1 and FEV1 /VC%, and PaO2,
those of PO were VC, FEV1 and FEV1 /VC%; no pre-
dictor was found for VO. In COPD the predictors of
CVD were age, GOLD class and sex; those of VO were
age, VC and MEF50, while the only predictor of PO was
BMI.
As shown in Table 8, the predictors of IHD were
COPD, age, BMI and FEV1 and those of PH, found only
in COPD patients, were VO (present in 80% of the pa-
tients) and FEV1.
The distributions of PO and VO by severity of asthma
(GINA) and COPD (GOLD) are reported in Figure 1. In
asthma, there is a clear increase in the prevalence of
both PO and VO with increasing the severity class, while
in COPD the prevalence of each type of CVD is similarTable 4 Comparisons among patients without cardiovascular
volume overload (VO) in COPD
COPD no CVD N. 12 PO N. 59 VO N. 58 Univ
Age, years 58.5 ± 2.6 66.7 ± 1.3 72.4 ± 1.0
Male, n (%) 9 (75) 37 (62.7) 32 (55.2)
BMI 25.4 ± 1.5 27.1 ± 0.7 25.4 ± 0.6
VC, % pred. 91.8 ± 3.12 85.3 ± 2.4 80.0 ± 2.9
FEV1,% pred 75.2 ± 4.8 66.3 ± 2.8 60.1 ± 2.8
FEV1/VC % 61.5 ± 3.8 58.8 ± 2.0 54.4 ± 1.9
MEF50, % pred 44.6 ± 10.2 34.5 ± 3.1 20.18 ± 2.1
CRP, mg/ml 4.4 ± 1.4 7.0 ± 0.9 8.9 ± 1.4in all classes. The comparison between chronic bron-
chitis and emphysema patients, shown in Table 9,
showed that the latter ones had older age, lower BMI,
more severe airway obstruction and higher prevalence of
heart volume overload and of pulmonary hypertension.
As one of the stronger predictors of CVD was age, we
made a sub-analysis on subjects with an age equal to 65
years or higher. As shown in Table 10, the prevalence of
CVD, PO and VO was similar in asthmatic and COPD
patients; the latter had higher prevalence of men,
smokers, lower FEV1, higher CRP and of IHD and PH.
The results of linear regression analysis in these older
patients are reported in Tables 11, 12 and 13.
Discussion
The results of this study show that patients with chronic
airway obstructive disorders, either asthma or COPD,
have increased prevalence of cardiovascular diseases as
compared to the general population of similar age [18].
The comparison between the two disorders, (see Table 1)
showed that CVD, particularly with volume overload,
was more frequent in COPD patients, who had also
older age, higher BMI, heavy smoking history, increased
CRP and greater airway obstruction. This finding is in
agreement with prior observations that in COPD
comorbidities are frequent and are sustained by systemicdisease (no CVD), with pressure overload (PO) and
ariate ANOVA no CVD vs PO no CVD vs VO PO vs VO
< 0.0001 0.012 < 0.0001 0.001
NS NS NS NS
NS NS NS NS
NS NS NS NS
0.048 NS 0.023 NS
NS NS NS NS
< 0.0001 NS < 0.0001 < 0.0001
NS NS NS NS
Table 5 Results of linear regression analysis for predictors of cardiovascular disease (CVD) in the overall patients
Asthma + COPD Non standardized coefficients Standardized coefficient t Sig.
B SD Error β
CVD
Constant .948 .248 3.829 .000
Age .012 .003 .340 4.357 .000
COPD .137 .063 .169 2.195 .030
Sex .116 .058 .144 1.991 .048
VC, % pred -.003 .002 -.124 −1.784 .076
MEF50, % pred -.002 .001 -.131 −1.728 .086
Pressure overload
Constant 1.066 .264 4.031 .000
COPD .217 .074 .225 2.939 .004
BMI .017 .007 .183 2.482 .014
VC, % pred -.006 .003 -.213 −2.031 .044
FEV1, % pred .007 .003 .322 2.162 .032
MEF50, % pred -.006 .002 -.305 −2.668 .008
Volume Overload
Constant 1.318 .446 2.954 .004
Age .015 .004 .310 3.529 .001
GINA/GOLD class -.118 .056 -.227 −2.113 .037
VC, % pred -.006 .003 -.197 −2.244 .027
MEF50, % pred -.005 .002 -.227 −2.094 .038
Table 6 Results of linear regression analysis for predictors of cardiovascular diseases (CVD) in asthma
ASTHMA Non standardized coefficients Standardized coefficient t Sig.
B SD Error β
CVD
Constant 8.291 1.056 7.851 .000
Age -.009 .005 -.270 −1.981 .059
BMI .016 .008 .223 1.874 .073
VC, % pred −.060 .009 −2.402 −6.630 .000
FEV1, % pred .073 .011 3.667 6.894 .000
FEV1/VC, % −.094 .013 −3.499 −7.021 .000
PaO2 −.010 .005 −.278 −2.268 .033
PRC .016 .009 .209 1.797 .085
Pressure Overload
Constant 6.668 1.082 6.163 .000
VC, % pred −.060 .012 −1.874 −5.078 .000
FEV1, % pred .067 .013 2.626 5.107 .000
FEV1/VC, % −.077 .016 −2.237 −4.690 .000
Volume Overload
Constant −.116 .693 −.167 .869
Age .019 .011 .320 1.822 .079
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Table 7 Results of linear regression analysis for predictors of cardiovascular diseases (CVD) in COPD
COPD Non standardized coefficients Standardized coefficient t Sig.
B SD Error β
CVD
Constant .686 .393 1.747 .084
Age .007 .003 .228 2.143 .035
GOLD Class .076 .036 .241 2.089 .040
Sex .121 .061 .203 1.983 .050
PaO2 .006 .003 .209 1.826 .071
Pressure Overload
Constant 1.237 .229 5.414 .000
BMI .020 .008 .244 2.337 .022
Volume Overload
Constant 1.317 .519 2.539 .013
Age .017 .005 .334 3.311 .001
VC, % pred −.006 .003 −.220 −2.076 .041
MEF50, % pred −.006 .003 −.305 −2.351 .021
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http://www.mrmjournal.com/content/8/1/58inflammation and by smoking [4,6,7]. The comparison
among patients without CVD, with PO and VO, showed
that both pressure and volume overload were associated
with older age and increased airway obstruction, either
in asthma or in COPD, (see Tables 2, 3 and 4). These
findings are in agreement with prior observations in
COPD [8-13,19]. Unfortunately, relatively little research
has been done in asthma [14]. It is generally believed
that the link between asthma and CVD is less strong
than that for COPD [14,20,21] and this applies particu-
larly to ischemic heart disease in asthmatic males. By
contrast, in women adult-onset asthma has been foundTable 8 Results of linear regression analysis for predictors of
(PH)







FEV1, % pred .007 .003




GOLD class −.105 .041
FEV1, % pred −.004 .002to be a significant risk factor for IHD and stroke [21,22].
Although only 8 of our asthmatic patients had IHD, as
many as 6 of them (75%) were never smoking women.
However, the strongest predictors of IHD were COPD,
age, BMI and FEV1, as previously suggested [19,23]. The
strong association of COPD with IHD is attributed to
the effect of cigarette smoking [19-24], and about 90% of
our COPD patients were past or present smokers. The
subanalysis of COPD patients with predominant chronic
bronchitis or emphysema, (see Table 9), showed that the
emphysema phenotype was associated with older age,
lower BMI, more severe airway obstruction and higherischemic heart disease (IHD) and pulmonary hypertension
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Distribution of heart disease by GOLD class
Figure 1 Distributions of heart pressure overload (PO) and volume overload (VO) by GINA asthma severity class (left graph), and by
GOLD COPD severity class (right graph).
Table 9 Comparison between general characteristics of patients with chronic bronchitis and emphysema
Chronic bronchitis Emphysema P
N. 102 N. 27
Age, years 68 ± 1.0 73 ± 1.5 0.017
BMI 27.2 ± 0.5 22.1 ± 0.6 < 0.0001
Male, n (%) 58 (56.9) 20 (74.1) NS
Smokers
current, n (%) 55 (53.9) 17 (63) NS
past, n (%) 33 (32.4) 9 (33.3) NS
Cardiovascular disease, n (%) 92 (90.2) 25 (92.6) NS
Pressure overload,n (%) 51 (50) 8 (29.6) NS
Volume overload, n (%) 41 (40.2) 17 (63) 0.034
Subgroup IHD n (%) 39 (39.4) 11 (40.7) NS
Subgroup PH n (%) 15 (4.7) 10 (37) 0.009
GOLD class
1 30 (29.4) 1 (3.7) 0.005
2 44 (43.1) 8 (29.6) NS
3 19 (18.6) 13 (48.1) 0.0016
4 9 (8.8) 5 (18.5) NS
VC, % predicted 82.7 ±2 85.5 ± 4.3 NS
FEV1, % predicted 68.1± 2.2 51.9 ± 3.1 0.001
FEV1/VC % 60.2 ± 1.4 46.56 ± 2.6 < 0.0001
MEF50, % predicted 33.7 ± 2.5 13.6 ± 2.1 < 0.0001
PaO2 , mmHg 71.2 ± 1.1 70.1 ± 2.1 NS
PaCO2 , mmHg 40.1 ± 0.6 39.0 ± 0.8 NS
CRP, mg/ml 7.9 ± 1.0 6.8 ± 1.2 NS
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Table 10 Comparisons between general characteristics of patients 65 years old or more
ASTHMA N. 33 COPD N. 92 P
Age, years 71.8 ± 0.8 73.6 ± 0.6 NS
Male, n (%) 5 (15.2) 60 (65.2) < 0.0001
Smokers
Current n(%) 4 (13) 45 (51) < 0.0001
Past n (%) 4 (13) 36 (41) < 0.0001
BMI 25.8 ± 0.8 26.2 ± 0.5 NS
CVD, n (%) 30 (90.9) 87 (94.6) NS
Pressure overload, n (%) 15 (45.5) 38 (41.3) NS
Volume overload, n (%) 15 (45.5) 49 (53.3) NS
Ischemic heart disease, n (%) 6 (18.2) 42 (46.7) 0.0054
Pulmonary hypertension, n (%) 0 21 (22.8) 0.0026
VC, % predicted 86.1 ± 2.6 82.7 ± 2.2 NS
FEV1, % predicted 73.3 ± 3.3 63.5 ± 2.3 0.023
FEV1/VC % 61.63 ± 2.5 56.4 ± 1.5 NS
MEF50, % predicted 30.8 ± 3.4 26.6 ± 2.3 NS
CRP, mg/l 4.1 ± 0.7 8.2 ± 1.0 0.018
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overload. Unfortunately, there are no data in the litera-
ture comparing CVD in the two COPD phenotypes.
As mentioned above, age and COPD were the stron-
gest predictors of CVD, but the two factors were closely
linked each other, as COPD patients were significantly
older than asthmatics. To clarify this point, we
performed a sub-analysis on patients with an age equalTable 11 Results of linear regression analysis for predictors o
old or more














VC, % predicted −.006 .003to or higher than 65 years. As shown in Table 10, older
asthmatics had the same prevalence of CVD than COPD
patients (91% versus 95%). However, also in the elderly,
the prevalence of IHD and PH was higher in COPD.
Pulmonary hypertension deserves a special comment.
PH in COPD is classically attributed to severe hypoxia
causing raised pulmonary pressures, but other factors
such as endothelial dysfunction or left heart disease, aref cardiovascular disease in the overall patients 65 years












Table 12 Results of linear regression analysis for predictors of cardiovascular disease in asthmatic patients 65 years
old or more
Asthma Non standardized coefficients Standardized coefficient t Sig.
B SD Error β
CVD
Constant 7.203 .662 10.885 .000
VC, % pred −.058 .007 −2.909 −8.345 .000
FEV1, % pred .064 .008 4.069 7.728 .000
FEV1/VC, % −.084 .011 −3.472 −7.509 .000
Pressure overload
Constant 3.616 1.487 2.432 .035
Age .028 .015 .250 1.913 .085
Sex .864 .152 .864 5.691 .000
GINA class −.380 .138 −.629 −2.766 .020
VC, % pred −.032 .010 −1.209 −3.306 .008
FEV1, % pred .033 .012 1.566 2.661 .024
FEV1/VC, % −.043 .015 −1.333 −2.785 .019
PaO2 −.017 .006 −.392 −2.954 .014
Volume overload
Constant .293 .874 .335 .739
Age .024 .011 .229 2.091 .040
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http://www.mrmjournal.com/content/8/1/58deemed to play a role [24]. In our patients, the predic-
tors of PH were FEV1 and volume overload, suggesting
that both airway obstruction and post capillary mecha-
nisms participated in increased pulmonary vascular re-
sistance. Actually, VO was present in 80% of patients
with PH.Table 13 Results of linear regression analysis for predictors o
more














VC, % predicted −.006 .004Conclusions
In conclusion, the results of this study indicate that car-
diovascular disease are frequent in patients with chronic
obstructive disorders, particularly COPD. The strongest
predictors of CVD are age and severity of airway ob-
struction. In older patients the prevalence of CVD isf cardiovascular disease in COPD patients 65 years old or
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http://www.mrmjournal.com/content/8/1/58similar in asthma and COPD, apart from ischemic heart
disease and pulmonary hypertension, which are strongly
associated with COPD.
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